1. Introduction {#sec1-cancers-12-00309}
===============

High-risk neuroblastoma defined by metastatic diseases over the age of 12 or 18 months \[[@B1-cancers-12-00309]\] and *MYCN* amplification at any age remain associated with long-term survival rates of only 40% \[[@B2-cancers-12-00309],[@B3-cancers-12-00309]\]. Treatment approaches comprise intensive induction \[[@B4-cancers-12-00309],[@B5-cancers-12-00309]\], consolidation with high-dose chemotherapy (HDT) and autologous stem cell rescue (ASCR) \[[@B3-cancers-12-00309],[@B6-cancers-12-00309]\], and isotretinoin as maintenance therapy.

As the disialoganglioside GD~2~ is expressed on the majority of neuroblastoma cells, with minimal expression on normal cells, it is a suitable target for immunotherapy \[[@B7-cancers-12-00309]\]. Therefore, human/mouse chimeric anti-GD~2~ antibody ch14.18, dinutuximab, produced in SP2/0 cells was developed and investigated in clinical trials \[[@B8-cancers-12-00309]\]. In Europe, ch14.18 was re-cloned in Chinese hamster ovarian (CHO) cells (dinutuximab beta) \[[@B9-cancers-12-00309]\] for clinical trials of International Society of Paediatric Oncology Europe Neuroblastoma Group SIOPEN. The tolerability and activity of dinutuximab beta was first evaluated in a dose schedule of 20 mg/m^2^ given on five consecutive days by an 8 h infusion \[[@B10-cancers-12-00309]\]. In 2006, SIOPEN opened a randomised trial to compare dinutuximab beta and isotretinoin with isotretinoin alone in patients with high-risk neuroblastoma. However, in 2007, the results of the Children's Oncology Group (COG) ANBL0032 trial were communicated, followed by publication in 2010 \[[@B7-cancers-12-00309]\], demonstrating that two-year event-free survival (EFS) and overall survival (OS) of patients with high-risk neuroblastoma receiving dinutuximab and cytokines (granulocyte-macrophage colony stimulating factor and interleukin-2), in addition to isotretinoin, were significantly higher by 20% and 11%, respectively \[[@B7-cancers-12-00309]\], compared to those patients receiving isotretinoin alone. Therefore, continuation of the SIOPEN randomised trial was believed to be no longer feasible nor considered ethical, and the study design was modified to allow all patients to receive dinutuximab beta with or without interleukin-2. The altered randomisation opened on 22 October 2009 to investigate the role of subcutaneous interleukin-2 (sc-IL-2) with dinutuximab beta and assigned patients to dinutuximab beta alone or with sc-IL-2 \[[@B11-cancers-12-00309]\]. All patients received oral isotretinoin \[[@B12-cancers-12-00309]\]. The trial showed that the addition of sc-IL-2 to immunotherapy with dinutuximab beta, given as an 8 h infusion, did not improve outcome but increased toxicity.

In this report, we aim to assess the contribution of dinutuximab beta-based immunotherapy to the outcome of patients with high-risk neuroblastoma in the International Society of Paediatric Oncology Europe Neuroblastoma Group High-Risk Neuroblastoma 1 (HR-NBL1/SIOPEN) trial by investigating the survival of patients in sequential eras with the same eligibility criteria treated with (immunotherapy population (IP), 2009--2013) \[[@B12-cancers-12-00309]\] or without immunotherapy (control population (CP), 2002--2009).

2. Results {#sec2-cancers-12-00309}
==========

2.1. Patient Characteristics {#sec2dot1-cancers-12-00309}
----------------------------

According to the inclusion criteria for the analysis, 844 patients enrolled in 146 SIOPEN member hospitals/institutions in 19 countries were eligible (378 in the IP and 466 in the CP) ([Figure 1](#cancers-12-00309-f001){ref-type="fig"}). Median follow-up was 5.8 years (inter-quartile range (IQR): 4.2 to 8.2 years). The median age of patients at diagnosis was 2.9 years (IQR: 1.8. to 3.8).

Both populations were balanced for sex, stage 4, *MYCN* amplification and response prior to HDT ([Table 1](#cancers-12-00309-t001){ref-type="table"}).

2.2. Survival {#sec2dot2-cancers-12-00309}
-------------

The five-year EFS was 57% (95% CI: 51--62%) for IP, compared to 42% (95% CI: 38--47%) for CP patients (*p* \< 0.001) ([Figure 2](#cancers-12-00309-f002){ref-type="fig"}A). The five-year overall survival (OS) for the IP was 64% (95% CI: 59--69%), compared to 50% (95% CI: 46-55%) for CP patients ([Figure 2](#cancers-12-00309-f002){ref-type="fig"}B).

The cumulative incidence of relapse/progression (CIR) at five years was 41% (95% CI: 37--47%) for the IP and 57% (95% CI: 53--61%) for the CP patients (*p* \< 0.001). At the last follow-up, 153 patients of the IP had an event versus 272 of CP patients. The cumulative incidence of non-relapse mortality was 2% (95% CI: 1--4%) in the IP and 1% (95% CI \< 1--2%) in the CP ([Figure 2](#cancers-12-00309-f002){ref-type="fig"}C).

2.3. Influence of Risk Factors {#sec2dot3-cancers-12-00309}
------------------------------

Disease status prior to maintenance therapy was available in 769/844 (91%) patients ([Table 2](#cancers-12-00309-t002){ref-type="table"}). Older age; stage 4; involvement of more than one metastatic compartment (MC); disease status prior to maintenance therapy; addition of topotecan, vincristine and doxorubicin (TVD) and use of carboplatin, etoposide and melphalan (CEM) as HDT were associated with lower EFS ([Figure 3](#cancers-12-00309-f003){ref-type="fig"}) in the population analysed. Patients with lymph nodes as their only MC (five-year EFS 60% (95% CI: 36--78%)) had a similar EFS as patients with other isolated metastatic sites (five-year EFS 60% (95% CI: 49--70%)).

In the IP, the two-year and five-year EFS rates for 210 patients (81 events) in complete remission (CR) were 68% (95% CI: 61--74%) and 61% (95% CI: 53--57%). In the CP, the two-year and five-year EFS rates for 258 patients in CR (144 events) were 54% (95% CI: 48--60%) and 46% (95% CI: 39--52%).

The impact of immunotherapy on EFS was significantly influenced by stage and MC, and the impact of immunotherapy was stronger in patients with metastatic disease ([Table 2](#cancers-12-00309-t002){ref-type="table"}). Furthermore, a borderline significant interaction between maintenance treatment and HDT (*p* = 0.055) was observed.

2.4. Multivariate Analysis on Analysis Cohort {#sec2dot4-cancers-12-00309}
---------------------------------------------

Patients who had no immunotherapy (*p* = \<.0001, cumulative hazard ratio (cHR) 1.75) HDT with CEM (*p* = 0.0345, cHR 1.3); partial remission (PR) prior maintenance therapy (*p* = 0.0103, cHR 1.49); more than one MC at diagnosis (*p* \< 0.001, cHR 2.69) and age \> 5 years (*p* = 0.0138, cHR 1.59) had a higher risk of relapse ([Table 3](#cancers-12-00309-t003){ref-type="table"}).

After adjustment for age, stage, MC, TVD and response prior to maintenance therapy ([Table 3](#cancers-12-00309-t003){ref-type="table"}), a benefit from immunotherapy was confirmed for either HDT (busulfan and melphalan (BuMel) or CEM). Patients receiving BuMel had an adjusted cumulative hazard ratio of 1.6 (1.2--2.1) with an unadjusted five-year EFS for the IP of 56% (95% CI: 50--61%) and 48% (95% CI: 41--54%) for the CP (*p* = 0.001). Patients receiving CEM had an adjusted cumulative hazard ratio of 3.0 (1.5--5.8) and showed an unadjusted five-year EFS of the IP of 67% (95% CI: 47--80%) versus 35% (95% CI: 29--42%) for the CP (*p* = 0.002).

2.5. Response to Maintenance Treatments {#sec2dot5-cancers-12-00309}
---------------------------------------

Thirty-nine of one hundred and eight (36%) CP patients with evaluable diseases prior to maintenance (67 very good partial remission (VGPR) and 41 partial remission (PR)) responded; of whom, 35/108 (32%) achieved CR after isotretinoin. In contrast, 64/130 (49%) of IP patients with evaluable diseases (85 VGPR and 45 PR) prior to immunotherapy responded; of whom, 52/130 (40%) achieved CR after immunotherapy ([Table 4](#cancers-12-00309-t004){ref-type="table"}, *p* = 0.226).

2.6. Adverse Events and Toxicity {#sec2dot6-cancers-12-00309}
--------------------------------

Adverse events (CTC Grades 1 to 4) are summarized in [Table 5](#cancers-12-00309-t005){ref-type="table"}. Toxicity tended to be higher in the IP population, particularly in those patients who received sc-IL-2. Four patients had non-relapse-related mortality in the IP and four in the CP.

3. Discussion {#sec3-cancers-12-00309}
=============

This analysis showed superior EFS and OS in the era when dinutuximab beta-based immunotherapy was included in therapy for high-risk neuroblastoma, compared to the previous era in the same trial when isotretinoin alone was the only element of maintenance therapy. Although there are limitations with a historical comparison, this is the first and possibly only demonstration that the addition of dinutuximab beta as immunotherapy improves survival in the high-risk neuroblastoma front-line population treated homogenously in the HR-NBL1/SIOPEN trial. Both the control and immunotherapy populations received the same treatment approach. Furthermore, this analysis is an important contribution, as data on the efficacy of anti-GD~2~ antibody-based immunotherapy are limited to one prospective randomised trial and a few retrospective analyses. Ethical concerns precluded a randomised comparison of immunotherapy after the results of the COG ANBL0032 trial emerged. A randomised trial of dinutuximab beta and isotretinoin compared to isotretinoin alone would have produced more robust data, but this was believed not to be ethically feasible within the SIOPEN community.

As the two cohorts were from the same trial and using the same criteria; in particular, HDT within nine months from diagnosis and no progression at 109 days after ASCR as a starting point for survival, with an unchanged supportive care protocol guidance, this analysis provides important data supporting the benefit of dinutuximab beta-based immunotherapy. The landmark time identified was the median time observed between ASCR and initiation of dinutuximab beta; thus, only patients without progressive diseases at this timepoint were included in the pre-immunotherapy CP. The introduction of this landmark was important in order to exclude early relapse before immunotherapy could be commenced. Both populations, IP and CP, were balanced for age, sex, stage 4, *MYCN* amplification and response prior to HDT.

The benefit of immunotherapy was further underpinned by multivariate analysis. After adjustment for risk factors (for example, age, stage, MC at diagnosis, need for TVD and response prior to maintenance therapy) a positive impact on outcome was observed with either BuMel or CEM. This is particularly important in view of a higher percentage of patients receiving CEM in the control group, as we previously have shown superior outcomes for patients treated with BuMel \[[@B6-cancers-12-00309]\]. Hence, the superior outcomes in the immunotherapy group are unlikely to be solely related to BuMel. These conclusions are supported by the recent publication from COG \[[@B13-cancers-12-00309]\] demonstrating that immunotherapy improves survival even after optimised HDT regimens.

Response prior to immunotherapy is an important prognostic factor. Patients treated in CR in the IP had a two-year EFS of 68%, compared to 54% in the CP. Acknowledging that comparisons across trials are challenging, these results are similar to the previous report of dinutuximab in combination with IL-2 and GM-CSF in patients in CR, resulting in a two-year EFS of 66% for patients treated by immunotherapy, compared to only 46% in patients with an isotretinoin maintenance treatment \[[@B7-cancers-12-00309]\]. Further support in favour of dinutuximab beta-based immunotherapy within the HR-NBl1/SIOPEN trial comes from improved response rates in patients with residual diseases at the site of the primary tumour or metaiodobenzylguanidine (mIBG)-positive skeletal disease following immunotherapy; a 49% response rate and a 40% CR rate was observed in patients treated with immunotherapy, as compared to a 36% overall response and 32% CR rate in the control population.

The increasing role for immunotherapy, with anti-GD~2~ antibodies, in the therapy of patients with high-risk neuroblastoma is further highlighted by the recent demonstration of the efficacy of combining anti-GD~2~ antibodies with chemotherapy, either at relapse or at initial presentation \[[@B14-cancers-12-00309],[@B15-cancers-12-00309]\].

In summary, this report describes the effects of including dinutuximab beta in high-risk neuroblastoma maintenance therapy and shows a clear survival benefit. This provides an important baseline to further build immunotherapy strategies in this challenging patient population.

4. Materials and Methods {#sec4-cancers-12-00309}
========================

4.1. Trial Eligibility {#sec4dot1-cancers-12-00309}
----------------------

HR-NBL1/SIOPEN, an international, randomised, multiarm, open-label, phase 3 trial for high--risk neuroblastoma, opened on 24 June 2002 and is registered with [ClinTrials.gov](ClinTrials.gov), number NCT01704716, and EudraCT, number 2006-001489-17. All randomisations of the HR-NBL1/SIOPEN trial are closed, and three have been published \[[@B5-cancers-12-00309],[@B6-cancers-12-00309],[@B12-cancers-12-00309]\]. SIOPEN institutions recruited patients after approval of the trial by national regulatory authorities and ethical committees. Parents/guardians and patients provided written informed consent or assent, when applicable.

The International Neuroblastoma Staging System criteria (INSS) and International Neuroblastoma Response Criteria (INRC) \[[@B16-cancers-12-00309]\] were used to classify the disease and to evaluate responses to therapy. Untreated patients with INSS stage 4 metastatic neuroblastoma aged 1-20 years or INSS stage 2--4 neuroblastoma with *MYCN* amplification, as determined in SIOPEN reference laboratories \[[@B17-cancers-12-00309]\], any age up to 20 years, were eligible. The SIOPEN-R-NET web-based system (<https://www.siopen-r-net.org/>) randomly assigned eligible patients in real-time.

4.2. Eligibiliy for the Analysis Cohort and Treatments Given {#sec4dot2-cancers-12-00309}
------------------------------------------------------------

This analysis included all patients registered in the HR-NBL1/SIOPEN trial between 2002 and 2013 who met the criteria: (i) HDT within 9 months from diagnosis and (ii) no progression at 109 days after ASCR. The median time between ASCR and initiation of dinutuximab beta was 109 days; therefore, only patients without progressive diseases at this landmark timepoint were included in the pre-immunotherapy control population (CP). The 18 patients randomised to receive dinutuximab beta and isotretinoin between 2006 and 2009 were excluded from this analysis. Two cohorts were compared, a CP between 2002--2009 who did not receive dinutuximab beta and an IP between 2009 and 2013 who was randomised to receive dinutuximab beta with or without sc-IL2 \[[@B12-cancers-12-00309]\]. As the addition of IL-2 to immunotherapy with dinutuximab beta did not improve outcome, both randomised arms were considered as one group for the purposes of this analysis \[[@B12-cancers-12-00309]\]. The CP comprised patients who received HDT randomised to BuMel or CEM \[[@B6-cancers-12-00309]\] but did not receive immunotherapy.

All patients received rapid COJEC induction \[[@B4-cancers-12-00309],[@B5-cancers-12-00309]\] ([Figure 4](#cancers-12-00309-f004){ref-type="fig"}). Between 2002 to 2010, patients who had a bone marrow complete response (CR) and a metastatic CR or a metastatic partial response (PR) defined by INSS criteria but at least 50% reduction in skeletal metaiodobenzylguanidine (mIBG) positivity from baseline and three or fewer areas of abnormal uptake on ¹²³I-mIBG scintigraphy were eligible for HDT randomisation comparing BuMel with CEM \[[@B6-cancers-12-00309]\]. Thereafter, BuMel became the standard of care. Patients who did not achieve a metastatic response to fulfil the HDT eligibility criteria received two courses of topotecan, vincristine and doxorubicin (TVD) \[[@B18-cancers-12-00309]\] prior to HDT. Local treatment of the primary tumour comprised attempted total surgical resection and radiotherapy (21 Gy) to the primary tumour site between 60 and 90 days after ASCR. There was no dose modification in the event of incomplete tumour excision; neither were metastatic sites systematically irradiated.

All patients received 6 cycles of oral isotretinoin over two weeks \[[@B3-cancers-12-00309]\] after local irradiation. From 2009, patients were randomised between day 60 to 90 after ASCR to receive five courses of dinutuximab beta at a dose of 20 mg/m^2^/day as an 8 h infusion for 5 consecutive days (total dose of 100 mg/m² per cycle, days 8 to 12) with or without 6 × 10^6^IU/m^2^/day of sc-IL-2 on days 1 to 5 and days 8 to 12 of each immunotherapy cycle \[[@B12-cancers-12-00309]\].

Patients had full disease evaluations prior to and after 2 and 5 courses of maintenance treatment. This included whole body ^123^I-mIBG scintigraphy, CT or MRI scans of the primary tumour and any other evaluable site of the disease; bone marrow examination with both aspirates and trephines obtained from two sites and measurement of urinary catecholamine metabolites. Response was assessed by the 1993 INRC based on local institution reporting. The only evaluable diseases prior to immunotherapy were mIBG-positive skeletal disease or diseases detectable on CT/MRI scans prior to randomisation, as patients with bone marrow involvement were not eligible.

4.3. Statistical Analysis {#sec4dot3-cancers-12-00309}
-------------------------

### 4.3.1. Establishment of the Analysis Cohort {#sec4dot3dot1-cancers-12-00309}

The number of MC at diagnosis was calculated according to the number of MC at diagnosis either in the bone marrow, skeleton or other sites, with a possible range from one to six. Characteristics of the CP were compared to the IP by the chi-square test to assess the balance of risk factors between the two populations.

### 4.3.2. Outcome Parameters {#sec4dot3dot2-cancers-12-00309}

Follow-up commenced at 109 days for the CP cohort and from the first dose of dinutuximab beta for the IP cohort. EFS and OS were estimated using the Kaplan and Meier method and compared with the log-rank test \[[@B19-cancers-12-00309]\]. CIR was estimated \[[@B20-cancers-12-00309]\], taking into account the competing risk of death without relapse/progression. For cumulative incidence of non-relapse mortality, relapse or progression was considered as a competing event. The statistical comparison of cumulative incidences used Gray's methodology \[[@B21-cancers-12-00309]\]. EFS, OS, cumulative incidence of relapse/progression and cumulative incidence of non-relapse mortality are presented as 5-year point estimates with confidence intervals (CI), as previously described \[[@B20-cancers-12-00309],[@B22-cancers-12-00309]\]. Two-year EFS was determined to facilitate comparisons with published data \[[@B7-cancers-12-00309]\]. *p*-values of less than 0.05 were considered to indicate statistical significance. In spite of the limitations of subgroup analysis (including multiple testing and lack of power), the cohorts were assessed according to baseline, pre and post-HDT risk factors ([Table 2](#cancers-12-00309-t002){ref-type="table"}). A formal test for interaction was performed within a Cox model.

### 4.3.3. Multivariate Analysis {#sec4dot3dot3-cancers-12-00309}

Multivariate analysis of treatment and risk factors was undertaken on the analysis cohort. In the presence of nonproportional hazards, as detected for age and *MYCN* amplification, the pseudo-value regression \[[@B22-cancers-12-00309]\] for a 5-year EFS approach was chosen. The aim of this analysis was to adjust the comparison between the two populations (IP and CP) for potential confounders and risk factors, such as age, stage, addition of TVD, disease status prior to maintenance and HDT/ASCR. Using the same approach, a subgroup analysis was performed in order to separately evaluate the value of immunotherapy in patients with BuMel and CEM.

The data cut-off time of this analysis was July 31, 2017. Median follow-up was calculated using the inverse Kaplan Meier estimate. The statistical evaluation and power calculation were done with SAS 9.4 and Module LR1 of Pass 2002, respectively.

5. Conclusions {#sec5-cancers-12-00309}
==============

This report shows that the introduction of dinutuximab beta is associated with a survival benefit for children with high-risk neuroblastoma. Similar results were reported for dinutuximab in one randomized trial and one nonrandomized investigation \[[@B23-cancers-12-00309],[@B24-cancers-12-00309],[@B25-cancers-12-00309]\]. However, dinutuximab beta is a different molecule with a separate development pathway, and the demonstration of its beneficial effects on treatment outcome is an important finding.

Given the absence of a beneficial effect by adding sc-IL-2 to an 8 h infusion of dinutuximab beta \[[@B12-cancers-12-00309]\], the standard treatment recommended by SIOPEN is dinutuximab beta with isotretinoin for maintenance therapy of high-risk neuroblastoma. The benefits might be less in some subgroups (\<1.5 years, *MYCN*-amplified localised disease) and needs close monitoring in future studies. Modifications of the length of the dinutuximab beta schedule and immunotherapy combination strategies may optimise the benefits of immunotherapy in high-risk neuroblastoma to improve survival.

Re-cloning and production of the ch14.18 monoclonal antibody was done at Polymun, Vienna, Austria and was enabled by a SIOPEN fundraising effort in 2001. APEIRON provided additional products at a later stage. Neither Polymun nor APEIRON had a role in the study design or analysis. The authors express their gratitude and appreciation to SIOPEN investigators, treating physicians, clinical research and care teams and most importantly to patients and families facing high-risk neuroblastoma for their committed participation in the trial. The authors are indebted to Ingrid Pribill for her important technical assistance in trial management and to Mag. Claudia Zeiner-Koglin for editorial assistance.
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![Influence of risk factors within the analysis population on event-free survival (EFS). (**A**) EFS and age; (**B**) EFS and stage; (**C**) EFS and metastatic compartments (MC) localised and 4s stage vs. stage 4 (one MC vs. multiple MC); (**D**) response status prior to maintenance phase: CR (complete remission), VGPR (very good partial remission) and PR (partial remission) and (**E**) EFS and TVD (topotecan, vincristine and doxorubicin). TVD added = yes and TVD not added = no. (**F**) Type of high-dose chemotherapy = BuMel (busulfan and melphalan) and CEM (carboplatin, etoposide and melphalan).](cancers-12-00309-g003){#cancers-12-00309-f003}
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cancers-12-00309-t001_Table 1

###### 

Characteristics of the control and immunotherapy populations. N = number; % = percentage; MNA = *MYCN* amplification; no = not present and yes = present; MC = metastatic compartments; TVD = topotecan, vincristine and doxorubicin; HDT = high-dose chemotherapy; BuMel = high-dose chemotherapy with busulfan and melphalan; CEM = high-dose chemotherapy with carboplatin, etoposide and melphalan; NR = not reported; CR = complete remission; VGPR = very good partial remission; PR = partial remission; CME = complete macroscopic excision and IME = incomplete macroscopic excision.

  Characteristics                Control Population   Immunotherapy Population                
  ------------------------------ -------------------- -------------------------- ----- ------ -----
  **Total**                      number               466                              378    
  **Sex**                        Female               180                        39%   140    37%
                                 Male                 286                        61%   238    63%
  **Age**                        \<1.5 years          64                         13%   55     14%
                                 1.5-\<5 years        333                        71%   254    67%
                                 ≥5 years             69                         15%   69     18%
                                 Median               2.70                             2.87   
  **Stage**                      Localised            60                         13%   32     8%
                                 Stage 4              406                        87%   339    90%
                                 Stage 4s             0                          0%    7      2%
  ***MYCN Stage 4***             *MNA NR*             27                         6%    16     4%
                                 MNA no               217                        57%   197    61%
                                 MNA yes              162                        43%   126    39%
  **MC**                         NR                   23                         5%    23     6%
                                 0                    60                         14%   32     9%
                                 1                    70                         16%   35     10%
                                 2                    136                        31%   112    32%
                                 3                    120                        27%   112    32%
                                 \>3                  57                         13%   64     18%
  **TVD given**                  NR                   23                         5%    10     3%
                                 No                   391                        88%   250    68%
                                 Yes                  52                         12%   118    32%
  **Surgery**                    CME                  318                        76%   261    75%
                                 IME                  101                        24%   87     25%
  **Status prior HDT**           NR                   25                         5%    33     9%
                                 CR                   174                        39%   116    34%
                                 VGPR                 159                        36%   149    43%
                                 PR                   108                        24%   80     23%
  **HDT**                        BuMel                257                        55%   348    92%
                                 CEM                  209                        45%   30     8%
  **Status prior Maintenance**   NR                   58                         12%   17     4%
                                 CR                   258                        63%   210    58%
                                 VGPR                 93                         23%   99     27%
                                 PR                   57                         14%   52     14%

cancers-12-00309-t002_Table 2

###### 

Outcomes according to risk factors and subgroups. (2A) Event-free survival and (2B) overall survival. Pts (patients); 95% CI (95% confidence interval); *p*- value (probability value for A: comparison according to risk factor and B: for interaction); MNA (*MYCN* amplification); - (not present) and + (present); MC (metastatic compartments); TVD (topotecan, vincristine and doxorubicin); HDT (high-dose chemotherapy); BuMel (high-dose chemotherapy with busulfan and melphalan); CEM (high-dose chemotherapy with carboplatin, etoposide and melphalan); CR (complete remission); VGPR (very good partial remission; PR (partial remission); CME (complete macroscopic excision) and IME (incomplete macroscopic excision).

  Characteristics                Total Population       Control Group               Immunotherapy Group       *p*-Value ^B^                                                                                                    
  ------------------------------ ---------------------- --------------------------- ------------------------- ------------------------- --------------------------- ---------------- --------------------------- ------------- -------
  **Total**                                             **844 Pts**                                                                     **466 Pts**                                  **378 Pts**                               
  **Sex**                        female                 164/320                     49 (44--55)               0.803                     105/180                     43 (36--50)      59/140                      57 (49--65)   0.938
                                 male                   273/524                     48 (44--52)                                         171/286                     41 (36--47)      102/238                     56 (49--62)   
  **Age**                        \<1.5 years            48/119                      60 (51--68)               0.007                     27/64                       59 (46--70)      21/55                       61 (47--73)   0.161
                                 1.5--\<5 years         302/587                     49 (44--53)                                         194/333                     42 (37--47)      108/254                     57 (50--63)   
                                 ≥5 years               87/138                      38 (30--47)                                         55/69                       25 (16--36)      32/69                       53 (40--64)   
  **Stage**                      Localised              25/92                       72 (62--80)               \<0.001                   14/60                       76 (63--85)      11/32                       66 (47--79)   0.007
                                 Stage 4                410/745                     45 (42--49)                                         262/406                     37 (32--42)      148/339                     56 (50--61)   
                                 Stage 4s               2/7                         71 (26--92)                                         --                          --               2/7                         71 (26--92)   
                                 Stage 4 MNA no--       236/414                     43 (38--48)               0.819                     147/217                     33 (27--39)      89/197                      54 (47--61)   0.25
                                 Stage 4 MNA yes+       154/288                     47 (41--53)                                         98/162                      42 (34--49)      56/126                      55 (45--63)   
  **MC**                         0                      25/92                       72 (62--80)               \<0.001                   14/60                       67 (63--85)      11/32                       66 (47--79)   0.025
                                 1                      43/105                      60 (50--69)                                         34/70                       54 (42--65)      9/35                        71 (50--85)   
                                 2                      136/248                     46 (39--52)                                         85/136                      39 (31--47)      51/112                      55 (45--63)   
                                 3                      134/232                     43 (36--49)                                         89/120                      27 (20--36)      45/112                      60 (50--69)   
                                 \>3                    76/121                      37 (28--46)                                         42/57                       28 (17--40)      34/64                       45 (32--57)   
  **TVD**                        no                     322/641                     50 (46--54)               0.024                     225/391                     44 (39--49)      97/250                      61 (54--67)   0.732
                                 yes                    100/170                     39 (32--47)                                         38/52                       27 (16--39)      62/118                      45 (34--55)   
  **Surgery**                    CME                    288/578                     50 (46--54)               0.123                     183/318                     43 (38--49)      105/260                     59 (52--65)   0.946
                                 IME                    106/188                     45 (38--52)                                         66/101                      38 (29--48)      40/87                       53 (42--63)   
  **Status Prior HDT**                                                                                                                                                                                                         
                                 CR                     134/290                     54 (48--59)               0.022                     86/174                      51 (43--58)      48/116                      57 (47--66)   0.294
                                 VGPR                   171/308                     45 (39--51)                                         104/159                     36 (29--44)      67/149                      55 (46--63)   
                                 PR                     104/188                     45 (38--53)                                         70/108                      38 (29--47)      34/80                       57 (45--67)   
  **Characteristics**            **Total Population**   **Control Group**           **Immunotherapy Group**   ***p*** **--value ^B^**                                                                                          
  **(A) Event Free Survival**    **Events/Pts**         **5--years EFS (95% CI)**   ***p*** **--value ^A^**   **Events/Pts**            **5--years EFS (95% CI)**   **Events/Pts**   **5--years EFS (95% CI)**                 
  **HDT**                        BuMel                  288/605                     52 (48--56)               \<0.001                   137/257                     48 (41--54)      151/348                     56 (50--61)   0.055
                                 CEM                    149/239                     39 (33--45)                                         139/209                     35 (29--42)      10/30                       67 (47--80)   
  **Status Prior Maintenance**                                                                                                                                                                                                 
                                 CR                     225/468                     52 (48--47)               0.002                     144/258                     46 (39--52)      81/210                      61 (53--67)   0.84
                                 VGPR                   98/192                      50 (42--56)                                         55/93                       43 (33--53)      43/99                       56 (46--66)   
                                 PR                     70/109                      35 (26--44)                                         42/57                       26 (15--33)      28/52                       45 (32--58)   
  **(B) Overall Survival**       **Events/ Pts**        **5-year OS (95% CI)**      ***p*** **-value ^A^**    **Events/Pts**            **5-year OS (95% CI)**      **Events/Pts**   **5-year OS (95% CI)**                    
  **Sex**                        female                 138/320                     59 (53--64)               0.536                     95/180                      53 (45--60)      43/140                      59 (53--64)   0.488
                                 male                   234/524                     55 (50--59)                                         150/286                     49 (43--55)      84/238                      55 (50--59)   
  **Age**                        \<1.5 years            45/119                      62 (52--70)               0.445                     26/64                       61 (48--72)      19/55                       62 (52--70)   0.409
                                 1.5--\<5 years         259/587                     57 (53--61)                                         177/333                     50 (45--55)      82/254                      57 (53--61)   
                                 ≥5 years               68/138                      49 (40--58)                                         42/69                       42 (30--54)      26/69                       49 (40--58)   
  **Stage**                      localised              24/92                       76 (66--83)               0.001                     13/60                       82 (69--89)      11/32                       76 (66--83)   0.003
                                 Stage 4                347/745                     54 (50--57)                                         232/406                     46 (41--51)      115/339                     54 (50--57)   
                                 Stage 4s               0/7                         83 (27--97)                                         0/0                                          1/7                                       
                                 Stage 4 MNA no-        193/414                     53 (47--58)               0.235                     129/217                     43 (37--50)      64/197                      53 (47--58)   0.150
                                 Stage 4 MNA yes+       137/288                     54 (48--60)                                         88/162                      49 (41--56)      49/126                      54 (48--60)   
  **MC**                         0                      24/92                       76 (66--83)               \<0.001                   13/60                       82 (69--89)      11/32                       76 (66--83)   0.013
                                 1                      36/105                      68 (58--76)                                         29/70                       62 (50--73)      7/35                        68 (58--76)   
                                 2                      109/248                     56 (50--62)                                         71/136                      51 (42--59)      38/112                      56 (50--62)   
                                 3                      117/232                     49 (42--56)                                         81/120                      36 (27--44)      36/112                      49 (42--56)   
                                 \>3                    70/121                      43 (34--52)                                         41/57                       32 (20--44)      29/64                       43 (34--52)   
  **TVD**                        no                     281/641                     57 (53--61)               0.224                     200/391                     52 (47--57)      81/250                      57 (53--61)   0.441
                                 yes                    78/170                      52 (44--60)                                         34/52                       36 (23--49)      44/118                      52 (44--60)   
  **Surgery**                    CME                    248/578                     57 (53--61)               0.218                     165/318                     51 (45--56)      83/260                      57 (53--61)   0.765
                                 IME                    91/188                      52 (45--59)                                         58/101                      46 (36--55)      33/87                       52 (45--59)   
  **Status Prior HDT**                                                                                                                                                                                                         
                                 CR                     116/290                     60 (54--66)               0.089                     80/174                      56 (48--63)      36/116                      60 (54--66)   0.522
                                 VGPR                   140/308                     55 (49--61)                                         86/159                      50 (42--58)      54/149                      55 (49--61)   
                                 PR                     92/188                      52 (45--59)                                         65/108                      44 (34--53)      27/80                       52 (45--59)   
  **HDT**                        BUMEL                  238/605                     60 (56--64)               \<0.001                   121/257                     56 (50--62)      117/348                     60 (56--64)   0.267
                                 CEM                    134/239                     46 (40--53)                                         124/209                     44 (37--50)      10/30                       46 (40--53)   
  **Characteristics**            **Total Population**   **Control Group**           **Immunotherapy Group**   ***p*** **--value ^B^**                                                                                          
  **(B) Overall Survival**       **Events/ Pts**        **5-year OS (95% CI)**      ***p*** **-value ^A^**    **Events/Pts**            **5-year OS (95% CI)**      **Events/Pts**   **5-year OS (95% CI)**                    
  **Status Prior Maintenance**                                                                                                                                                                                                 
                                 CR                     190/468                     60 (55--65)               0.006                     129/258                     54 (47--59)      61/210                      60 (55--65)   0.640
                                 VGPR                   83/192                      57 (49--64)                                         47/93                       52 (42--62)      36/99                       57 (49--64)   
                                 PR                     61/109                      43 (33--53)                                         38/57                       36 (23--48)      23/52                       50 (33--65)   

cancers-12-00309-t003_Table 3

###### 

Multivariate analysis of the analysis cohort. cHR (cumulative hazard ratios); 95% CI (95% confidence interval); *p*-value (probability value); MNA (*MYCN* amplification); MC (metastatic compartments, referring either to bone marrow, skeletal or lymph node involvement); TVD (topotecan, vincristine and doxorubicin); CR (complete remission); VGPR (very good partial remission); PR (partial remission); HDT (high-dose chemotherapy); BuMel (high-dose chemotherapy with busulfan and melphalan); CEM (high-dose chemotherapy with carboplatin, etoposide and melphalan); IP (immunotherapy population) and CP (control population). \* test for the global main effect for risk-factors with more than two categories.

            Risk Factor                                                                                                               Characteristics     Pseudo Values for 5-Years EFS   
  --------- ------------------------------------------------------------------------------------------------------------------------- ------------------- ------------------------------- ----------
  **(A)**   **Multivariate Analysis**                                                                                                                                                     
            **Immunotherapy vs. Control Cohort**                                                                                      1.75 (1.36--2.25)   \<0.0001                        
            **Age (vs. \<1.5 yrs)**                                                                                                                       0.0931 \*                       
                                                                                                                                      **1.5--5 years**    1.31 (0.92--1.87)               0.1384
                                                                                                                                      **\>5years**        1.59 (1.05--2.42)               0.0138
            **Stage 4, 4s and Number of MC (vs. MNA stages 2, 3)**                                                                                        \<0.0001 \*                     
                                                                                                                                      **1 MC**            1.38 (0.80--2.47)               0.2493
                                                                                                                                      **\>1MC**           2.69 (1.74--4.15)               \<0.0001
            **TVD**                                                                                                                                       1.28 (0.97--1.69)               0.2478
            **Status Prior Maintenance (vs. CR)**                                                                                                         0.0363 \*                       
                                                                                                                                      **VGPR**            1.06 (0.81--1.39)               0.6416
                                                                                                                                      **PR**              1.49 (1.10--2.02)               0.0103
            **HDT**                                                                                                                   **CEM vs. BuMel**   1.32 (1.02--1.70)               0.0345
  **(B)**   **Subgroup Analysis According to HDT(after adjustment for age, stage, MC, TVD and status prior maintenance treatment)**                                                       
            **BUMEL**                                                                                                                 **IP vs. CP**       1.6 (1.2--2.1)                  0.001
            **CEM**                                                                                                                   **IP vs. CP**       3.0 (1.5--5.8)                  0.002

cancers-12-00309-t004_Table 4

###### 

Response for immunotherapy and control populations. Legend: CR (complete remission), VGPR (very good partial remission), PR (partial remission), SD (stable disease) and PD (progressing disease).

  Response Status before Maintenance   Response Status after Maintenance                                                                                      
  ------------------------------------ ----------------------------------- --------- --------- ------------------------------------ -------- -------- ------- --------
                                                                                               **Immunotherapy and Isotretinoin**                             
  **CR**                                                                   **210**   **188**   **151**                              **0**    **0**    **0**   **37**
  **\<CR**                             **Total**                           **151**   **130**   **52**                               **43**   **8**    **0**   **27**
                                       **VGPR**                            99        85        36                                   31       0        0       18
                                       **PR**                              52        45        16                                   12       8        0       9
                                                                                               **Isotretinoin**                                               
  **CR**                                                                   **258**   204       163                                  0        0        0       40
  **\<CR**                             **Total**                           **150**   **108**   **35**                               **27**   **18**   **1**   **27**
                                       **VGPR**                            93        67        28                                   23       2        0       14
                                       **PR**                              57        41        7                                    4        16       1       13

cancers-12-00309-t005_Table 5

###### 

Toxicities IL-2 (interleukin 2), non-hem. tox. (non-hematological toxicities), WBC (white blood cells), ECHO LV (left ventricular)/SV (stroke volume), GFR (glomerular filtration rate), central neuro (central neurotoxicity), periph neuro (peripheral neurotoxicity) and liver enzymes: SGOT (serum-glutamat-oxalacetat-transaminase)/SGPT (serum-glutamat-pyruvat-transaminase). Columns in bold show the values for the combined grade 3 and 4 toxicities.

  Toxicities                        Control   Without IL2              With IL2                                                                                                                            
  --------------------------------- --------- ------------- ---- ----- ---------- ---- -------- --------- ----- ----- ---- ----- ----- ---- --------- --------- ----- ----- ---- ---- ----- ---- --------- ---------
  **Non-Hem. Tox.**                 317       113           42   116   41         5    **46**   **15%**   186   5     6    53    105   17   **122**   **66%**   192   4     2    20   113   53   **166**   **86%**
  **General Condition**             314       225           69   13    4          3    **7**    **2%**    185   42    70   43    24    6    **30**    **16%**   192   25    53   36   66    12   **78**    **41%**
  **Haemoglobin**                   313       208           39   54    8          4    **12**   **4%**    186   21    2    84    69    10   **79**    **42%**   191   14    5    46   102   24   **126**   **66%**
  **WBC**                           313       235           32   28    15         3    **18**   **6%**    186   35    30   73    42    6    **48**    **26%**   191   35    30   57   51    18   **69**    **36%**
  **Granulocytes**                  313       244           23   25    16         5    **21**   **7%**    186   44    26   54    43    19   **62**    **33%**   191   34    12   34   69    42   **111**   **58%**
  **Platelets**                     313       260           13   12    16         12   **28**   **9%**    186   66    25   31    40    24   **64**    **34%**   191   30    18   26   61    56   **117**   **61%**
  **Infection**                     315       220           52   23    19         1    **20**   **6%**    185   79    26   32    47    1    **48**    **26%**   191   60    20   47   58    6    **64**    **34%**
  **Fever**                         314       241           14   54    4          1    **5**    **2%**    185   41    3    116   24    1    **25**    **14%**   190   28    4    82   66    10   **76**    **40%**
  **Stomatitis**                    312       293           10   7     2          0    **2**    **1%**    185   156   18   8     0     3    **3**     **2%**    191   149   27   12   2     1    **3**     **2%**
  **Nausea/Vomiting**               313       284           6    19    4          0    **4**    **1%**    185   88    11   76    9     1    **10**    **5%**    191   68    12   94   14    3    **17**    **9%**
  **Diarrhoea**                     313       286           11   13    3          0    **3**    **1%**    185   93    32   47    10    3    **13**    **7%**    192   75    25   51   34    7    **41**    **21%**
  **Constipation**                  312       302           7    3     0          0    **0**    **0%**    185   110   43   32    0     0    **0**     **0%**    191   142   21   21   4     3    **7**     **4%**
  **Skin**                          315       181           50   73    10         1    **11**   **3%**    185   65    46   65    9     0    **9**     **5%**    192   48    48   77   19    0    **19**    **10%**
  **Allergy**                       314       307           4    3     0          0    **0**    **0%**    185   88    50   28    14    5    **19**    **10%**   191   75    39   38   32    7    **39**    **20%**
  **Cardiac Function**              298       298           0    0     0          0    **0**    **0%**    182   178   0    0     3     1    **4**     **2%**    191   183   3    1    3     1    **4**     **2%**
  **Echo LV/SV**                    298       298           0    0     0          0    **0**    **0%**    182   181   0    0     0     1    **1**     **1%**    189   181   5    2    0     1    **1**     **1%**
  **Hypotension**                   298       296           2    0     0          0    **0**    **0%**    182   139   22   8     12    1    **13**    **7%**    191   119   23   17   25    7    **32**    **17%**
  **Hypertension**                  298       298           0    0     0          0    **0**    **0%**    182   162   10   3     7     0    **7**     **4%**    190   177   4    6    3     0    **3**     **2%**
  **Creatinine**                    312       301           9    2     0          0    **0**    **0%**    185   167   14   1     3     0    **3**     **2%**    192   159   20   11   2     0    **2**     **1%**
  **Proteinuria**                   311       307           4    0     0          0    **0**    **0%**    184   169   13   2     0     0    **0**     **0%**    191   178   12   1    0     0    **0**     **0%**
  **Haematuria**                    311       305           6    0     0          0    **0**    **0%**    183   167   11   5     0     0    **0**     **0%**    191   169   16   6    0     0    **0**     **0%**
  **GFR**                           310       302           5    3     0          0    **0**    **0%**    183   172   6    2     3     0    **3**     **2%**    190   179   9    1    1     0    **1**     **1%**
  **Central Neuro**                 311       304           4    0     0          3    **3**    **1%**    185   165   14   3     3     0    **3**     **2%**    191   158   16   6    3     8    **11**    **6%**
  **Periph Neuro**                  311       308           1    0     1          1    **2**    **1%**    185   173   8    3     1     0    **1**     **1%**    191   167   14   4    5     1    **6**     **3%**
  **Bilirubin**                     309       301           4    2     2          0    **2**    **1%**    185   169   1    10    4     1    **5**     **3%**    192   159   5    21   6     1    **7**     **4%**
  **SGOT/SGPT**                     311       218           68   19    6          0    **6**    **2%**    185   68    43   43    30    1    **31**    **17%**   192   68    40   40   43    1    **44**    **23%**
  **Dilated Pupils**                22        22            0    0     0          0    **0**    **0%**    123   108   15   0     0     0    **0**     **0%**    125   95    30   0    0     0    **0**     **0%**
  **Accommodation Defects**         22        22            0    0     0          0    **0**    **0%**    121   115   6    0     0     0    **0**     **0%**    125   111   14   0    0     0    **0**     **0%**
  **Capillary Leak Syndrome**       19        18            0    1     0          0    **0**    **0%**    119   91    0    23    5     0    **5**     **4%**    124   70    0    35   16    3    **19**    **15%**
  **Cytokine Release Syndrome**     19        18            1    0     0          0    **0**    **0%**    118   95    8    10    5     0    **5**     **4%**    123   85    12   17   9     0    **9**     **7%**
  **Pain related to ch14.18/CHO**                                                                         122   42    17   44    19    0    **19**    **16%**   124   28    22   42   31    1    **32**    **26%**
  **Papilloedema**                  22        22            0    0     0          0    **0**    **0%**    120   113   7    0     0     0    **0**     **0%**    123   121   2    0    0     0    **0**     **0%**

[^1]: The authors contributed equally to this work and share first authorship.
